We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.28%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$959M
AUM Growth
+$88.6M
Cap. Flow
-$54.3M
Cap. Flow %
-5.67%
Top 10 Hldgs %
33.04%
Holding
103
New
15
Increased
39
Reduced
35
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$17.6M
2
BSX icon
Boston Scientific
BSX
+$15.7M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.6M
4
MCK icon
McKesson
MCK
+$7.81M
5
FOLD
Amicus Therapeutics
FOLD
+$7.68M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$18.7M
2
LLY icon
Eli Lilly
LLY
+$17.3M
3
THC icon
Tenet Healthcare
THC
+$16.8M
4
RVTY icon
Revvity
RVTY
+$15.2M
5
COO icon
Cooper Companies
COO
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
26
PTC Therapeutics
PTCT
$6.06B
$12.4M 1.3%
202,363
+20,720
+11% +$1.08M
ACLX
27
DELISTED
Arcellx
ACLX
$12.3M 1.28%
149,848
-24,428
-14% -$1.76M
EW icon
28
Edwards Lifesciences
EW
$53.6B
$12.1M 1.26%
155,766
-95,975
-38% -$7.5M
COO icon
29
Cooper Companies
COO
$15B
$12.1M 1.26%
176,523
-208,956
-54% -$14.8M
WAY
30
Waystar Holding Corp
WAY
$4.71B
$11.6M 1.21%
306,027
+166,027
+119% +$6.15M
DXCM icon
31
DexCom
DXCM
$34.3B
$11.5M 1.2%
171,628
-54,247
-24% -$4.29M
CSTL icon
32
Castle Biosciences
CSTL
$960M
$10.8M 1.13%
475,568
+123,306
+35% +$2.5M
OPRX icon
33
OptimizeRx
OPRX
$132M
$10.4M 1.09%
509,611
+2,188
+0.4% +$34.7K
NUVL
34
DELISTED
Nuvalent
NUVL
$10.4M 1.08%
120,190
+567
+0.5% +$44.8K
ATEC icon
35
Alphatec Holdings
ATEC
$1.49B
$10.1M 1.06%
696,980
+48,109
+7% +$670K
AORT icon
36
Artivion
AORT
$1.4B
$9.36M 0.98%
221,044
+28,339
+15% +$1.07M
UTHR icon
37
United Therapeutics
UTHR
$21.9B
$9.22M 0.96%
22,000
+13,189
+150% +$4.44M
AXGN icon
38
Axogen
AXGN
$2.67B
$8.95M 0.93%
501,832
-172,719
-26% -$2.51M
EWTX icon
39
Edgewise Therapeutics
EWTX
$4.73B
$8.92M 0.93%
550,173
-97,158
-15% -$1.38M
RCUS icon
40
Arcus Biosciences
RCUS
$3.69B
$8.88M 0.93%
652,680
+53,070
+9% +$552K
INCY icon
41
Incyte
INCY
$24.5B
$8.52M 0.89%
100,442
+25,442
+34% +$2.01M
TVTX icon
42
Travere Therapeutics
TVTX
$5.86B
$8.12M 0.85%
339,764
-487,296
-59% -$9.16M
URGN icon
43
UroGen Pharma
URGN
$2.39B
$8.03M 0.84%
402,595
+225,893
+128% +$4.06M
ASND icon
44
Ascendis Pharma A/S
ASND
$16.8B
$8.02M 0.84%
40,343
-1,765
-4% -$329K
AMLX icon
45
Amylyx Pharmaceuticals
AMLX
$2.6B
$7.87M 0.82%
579,174
-70,826
-11% -$667K
BCRX icon
46
BioCryst Pharmaceuticals
BCRX
$2.71B
$7.69M 0.8%
1,012,664
+4,672
+0.5% +$38.9K
VCYT icon
47
Veracyte
VCYT
$3.59B
$7.66M 0.8%
223,065
+2,678
+1% +$76.8K
LLY icon
48
Eli Lilly
LLY
$1.09T
$7.63M 0.8%
10,000
-23,296
-70% -$17.3M
QDEL icon
49
QuidelOrtho
QDEL
$1.02B
$7.45M 0.78%
252,817
-133,829
-35% -$3.66M
XENE icon
50
Xenon Pharmaceuticals
XENE
$6.31B
$7.07M 0.74%
176,137
+25,764
+17% +$907K
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Parkman Healthcare Partners held 103 positions worth $959M, up 10% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $54.3M in Q3 2025, closing 12 positions and reducing 35 holdings. Its most notable exit was Verona Pharma, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

Against the trend, Parkman Healthcare Partners opened a new position in Biogen worth $18.2M.

  • Parkman Healthcare Partners's largest Q3 2025 buy was Biogen: 130,165 shares worth $18.2M.
  • Parkman Healthcare Partners added most to Boston Scientific in Q3 2025, an estimated $15.7M increase.
  • Parkman Healthcare Partners's biggest Q3 2025 reduction was Eli Lilly, cutting an estimated $17.3M.
  • Parkman Healthcare Partners fully exited Verona Pharma in Q3 2025, selling an estimated $18.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $959M portfolio in Q3 2025.
  • Parkman Healthcare Partners opened 15 new positions and closed 12 in Q3 2025.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $959M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.